Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03526224 · ClinicalTrials.gov registry record
Teriflunomide Tecfidera LMCE
A clinical trial, sponsored by University at Buffalo.
- Completed
- Registry status
- 120
- Enrollment target
NCT03526224 is a clinical trial that has completed, run by University at Buffalo. The registered enrollment target is 120 participants.
The verdict
NCT03526224 has completed, sponsored by University at Buffalo.
- COMPLETED
- Registry status
- 120 participants
- Enrollment target
Study Summary
This study will investigate the effect of teriflunomide in reducing cortical gray matter (CGM) atrophy and leptomeningeal (LM) inflammation over 24 months compared to dimethyl fumarate (Tecfidera®)
Interventions
- DRUG Teriflunomide
- DRUG Dimethyl Fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2018-06-14 |
| Est. Completion | 2019-07-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03526224
The ClinicalTrials.gov registry entry for NCT03526224 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University at Buffalo, which has 67 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Teriflunomide is the first listed.
NCT03526224 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03526224 about?
NCT03526224 is a clinical study titled "Teriflunomide Tecfidera LMCE". This study will investigate the effect of teriflunomide in reducing cortical gray matter (CGM) atrophy and leptomeningeal (LM) inflammation over 24 months compared to dimethyl fumarate (Tecfidera®)
What is the current status of trial NCT03526224?
This trial is currently completed. The enrollment target is 120 participants. The study started on 2018-06-14. Estimated completion is 2019-07-10.
What interventions are being tested in trial NCT03526224?
The interventions under investigation include: Teriflunomide (DRUG), Dimethyl Fumarate (DRUG).
Who is sponsoring clinical trial NCT03526224?
This trial is sponsored by University at Buffalo, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.